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Abstract
The rise of resistance together with the shortage of new broad-spectrum antibiotics underlines the urgency of optimizing
the use of available drugs to minimize disease burden. Theoretical studies suggest that coordinating empirical usage of
antibiotics in a hospital ward can contain the spread of resistance. However, theoretical and clinical studies came to
different conclusions regarding the usefulness of rotating first-line therapy (cycling). Here, we performed a quantitative
pathogen-specific meta-analysis of clinical studies comparing cycling to standard practice. We searched PubMed and
Google Scholar and identified 46 clinical studies addressing the effect of cycling on nosocomial infections, of which 11 met
our selection criteria. We employed a method for multivariate meta-analysis using incidence rates as endpoints and find that
cycling reduced the incidence rate/1000 patient days of both total infections by 4.95 [9.43–0.48] and resistant infections by
7.2 [14.00–0.44]. This positive effect was observed in most pathogens despite a large variance between individual species.
Our findings remain robust in uni- and multivariate metaregressions. We used theoretical models that reflect various
infections and hospital settings to compare cycling to random assignment to different drugs (mixing). We make the realistic
assumption that therapy is changed when first line treatment is ineffective, which we call ‘‘adjustable cycling/mixing’’. In
concordance with earlier theoretical studies, we find that in strict regimens, cycling is detrimental. However, in adjustable
regimens single resistance is suppressed and cycling is successful in most settings. Both a meta-regression and our
theoretical model indicate that ‘‘adjustable cycling’’ is especially useful to suppress emergence of multiple resistance. While
our model predicts that cycling periods of one month perform well, we expect that too long cycling periods are detrimental.
Our results suggest that ‘‘adjustable cycling’’ suppresses multiple resistance and warrants further investigations that allow
comparing various diseases and hospital settings.
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Introduction
The emergence and spread of antibiotic resistance threatens our
ability to treat bacterial infections and is a substantial danger for
public health world-wide [1]. Resistant strains are especially
prevalent in hospitals, where the high usage of antibiotics
facilitates emergence and spread of resistant strains. Globally,
8% of hospital stays result in nosocomial infections [1]. It has been
estimated that 70% of these are caused by single- or multiple-
resistant bacteria [2]. Compared to infections by susceptible
bacteria, those caused by resistant strains often increase mortality,
morbidity and costs [3]. While treatment can be tailored to the
pathogen and its resistance profile once cultures are available,
treatment typically needs to be initiated immediately. This
treatment phase is called empirical therapy. In single hospitals
or wards, population-wide empirical treatment of patients can be
coordinated, and several such strategies have been proposed to
fight resistance [4–10]. Here, we focus on the comparison of two
strategies on which most clinical and theoretical studies have
focused so far: The first is ‘‘cycling’’ i.e. scheduled changes of the
predominant antibiotic in a whole ward or hospital. The second is
‘‘mixing’’ i.e. the random assignment of patients to different
antibiotics, such that at any given time point multiple antibiotics
are employed in approximately equal proportions. Mixing has
been seen as the strategy closest to the current usage patterns in
most wards [5]. Theoretical models predict that, when different
antibiotics are employed at comparable average frequencies,
mixing should outperform cycling since the pathogen is subject to
greater environmental heterogeneity when transmitted from host
to host [5,6]. Clinical studies addressing the general usefulness of
cycling have come to contradictory results. Not only has no clear
pattern emerged from these studies, but also some studies report
divergent outcomes for different pathogen species. A qualitative
meta-analysis [10] has argued that cycling could be beneficial for
preserving drug susceptibility in Pseudomonas aeruginosa. However,
neither a quantitative pathogen specific meta-analysis, nor a
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to date.
Despite the difficulties to exclude confounders in the clinical
setting and the often-criticized study designs [11], it may therefore
be worth to re-evaluate both clinical studies and theoretical
models. Specifically, it is important to elucidate whether inherent
characteristics of the pathogen or the host populations may lead to
these different outcomes. Here, we perform a quantitative and
pathogen-specific meta-analysis of clinical studies comparing
cycling to standard treatment regimens. We furthermore develop
an epidemiological model tailored to the situation in hospital
wards. We design this model such that it can easily describe a
multitude of infectious diseases. Furthermore, we aim at a model
structure that allows parameterization with observed clinical
parameters. Earlier theoretical studies assumed that patients
remained on the prescribed drugs until leaving the hospital (‘‘strict
cycling’’/‘‘strict mixing’’). Here, we make the realistic assumption
that empirical therapy is automatically changed when ineffective
(‘‘adjustable cycling’’/‘‘adjustable mixing’’). For the sake of clarity,
we will refer to any clinical cycling schedules as ‘‘clinical cycling’’,
because clinical reality is likely different from these two extremes.
We compare the results of our meta-analysis with the predictions
of our theoretical model and highlight common observations that
may explain the divergence between earlier studies.
Results
Unfortunately, morbidity and mortality attributable to resistant
nosocomial infections are only known for a few pathogens [12].
Therefore, we need measurable proxies for disease burden.
Hospital-acquired infections with both susceptible and resistant
pathogens increase morbidity and mortality. In both our meta-
analyses and the epidemiological model, we follow the total
number of patients infected with either resistant or susceptible
strains. Moreover, it has been shown that patient outcome is worse
when receiving inappropriate therapy, i.e. being assigned to an
ineffective initial treatment [13,14]. In our epidemiological model,
we can quantify inappropriately treated patients. However, there
are no matched data for resistance profile and antibiotic therapy
provided in any of the clinical studies. We chose the incidence rate
of resistant infections as second endpoint in the meta-analysis,
because having a resistant infection increases the probability of
inappropriate therapy.
Analysis of clinical data
Here, we define clinical cycling as repeated rotations of at least
two antibiotics in the same order. We performed a literature
search (see methods) to identify studies meeting these criteria. For
performing a quantitative meta-analysis, we required the following
additional criteria: i) a baseline period in the same ward or
comparison to simultaneously recorded data from a ward in the
same hospital, ii) no other infection control measures introduced in
the observation period and iii) unprocessed data on the number of
isolates.
As explained above, we chose the number of total isolates and
resistant isolates per patient day as primary endpoints. Addition-
ally, we collected data on mortality as a secondary endpoint. To be
able to link resistance evolution to the used antibiotics and to
compare the results to our epidemiological model, we only
included resistance against the scheduled antibiotics. To account
for multiple resistance, we summed over the number of isolates
against each of the employed drugs (later referred to as weighted
incidence rate of resistant infections). Moreover, we extracted data
on mortality as a secondary endpoint to ascertain that cycling has
no unexpected detrimental effects. We identified 46 studies [15–
59], of which 11 were eligible [45–54,59], i.e. fulfilled our criteria
and provided all needed data (Figure S1, Table S1 and methods).
One of these [51] reported outcomes from independent wards,
which we report separately. Table S2 lists all data extracted from
these studies.
For all endpoints, cycling performed significantly better in
univariate analyses, also after adjustment for multiple testing
(Table S3). However, the three endpoints are correlated (not
independent), such that univariate meta-analyses on each individ-
ual endpoint is inferior to a multivariate meta-analysis on those
three endpoints simultaneously. We employed a multivariate
analysis framework (methods and supplementary materials p. 9),
which revealed significant reductions in the weighted incidence
rate of resistant isolates from 27 to 20 isolates/1000 patient days
(p=0.037) as well as in the total incidence rate from 30 to 25
isolates/1000 patient days (p=0.03, Figure 1A).
We found a pronounced correlation (p=0.00059, p=0.028
after Benjamini-Hochberg correction for multiple testing) between
the total incidence rate and level of resistance against the cycled
drugs during the baseline period as measured in average number
of resistances per isolate (Figure 1B). At low levels of baseline
resistance, clinical cycling reduced the total incidence rate of
resistant infections substantially.
Because of the enormous biological differences between the
various bacterial pathogens that may cause hospital-acquired
infections, we repeated our analysis for single pathogen groups and
species (Figure 1C). While clinical cycling remains overall
beneficial, its success strongly depended on the pathogen species.
Differences in antibiotic consumption and import of resistance
into the hospital are strong confounders when comparing
strategies to fight resistance. It has e.g. been argued that
conducting a study per se might alter prescription behavior and
thus reduce antibiotic usage and increase antibiotic heterogeneity
[60]. We collected data on overall antibiotic heterogeneity during
baseline and clinical cycling (in this case measured over all
Author Summary
The rise of antibiotic resistance is a major concern for
public health. In hospitals, frequent usage of antibiotics
leads to high resistance levels; at the same time the
patients are especially vulnerable. We therefore urgently
need treatment strategies that limit resistance without
compromising patient care. Here, we investigate two
strategies that coordinate the usage of different antibiotics
in a hospital ward: ‘‘cycling’’, i.e. scheduled changes in
antibiotic treatment for all patients, and ‘‘mixing’’, i.e.
random assignment of patients to antibiotics. Previously,
theoretical and clinical studies came to different conclu-
sions regarding the usefulness of these strategies. We
combine meta-analyses of clinical studies and epidemio-
logical modeling to address this question. Our meta-
analyses suggest that cycling is beneficial in reducing the
total incidence rate of hospital-acquired infections as well
as the incidence rate of resistant infections, and that this is
most pronounced at low baseline levels of resistance. We
corroborate our findings with theoretical epidemiological
models. When incorporating treatment adjustment upon
deterioration of a patient’s condition (‘‘adjustable cy-
cling’’), we find that our theoretical model is in excellent
accordance with the clinical data. With this combined
approach we present substantial evidence that adjustable
cycling can be beneficial for suppressing the emergence of
multiple resistance.
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imported pathogens. We obtained very similar estimates for the
effect of clinical cycling (Table 1) when adjusting for these three
confounders in a multivariate meta-regression. A sensitivity
analysis of the results can be found in the supplementary material
(text S1, {table S4, S5).
Theoretical model
We used our epidemiological model to investigate whether we
could find theoretical explanations for the results of our meta-
analysis. Unlike previous work, our model distinguishes between
asymptomatically colonized and symptomatically infected patients.
In particular, we make the realistic assumption that treatment is
adapted if an asymptomatically colonized patient progresses to
symptomatic disease. For instance, patients receiving drug A are
switched to drug B when their condition deteriorates. In clinical
practice, it may be impossible to adhere to the current treatment
regimen under all circumstances. To accommodate for variable
adherence, we include patients treated with neither of the
scheduled drugs as well as patients treated with both drugs
simultaneously. We also consider two transmission modes: delayed
transmission via contaminated surfaces and direct transmission.
Furthermore, we consider a stochastic and a deterministic version,
which describe small populations (i.e. single wards) and large
populations (i.e. entire hospitals), respectively.
We employed our model to address how the benefit of
‘‘adjustable cycling’’ changes with the period length. Figure 2
gives an overview of the dynamics during different period lengths.
For the extremes of the screened period range, our findings are
in accordance with previous studies (Figure 3, S2, and S3). For
periods below 5 days, there is no difference between ‘‘adjustable
cycling’’ and ‘‘adjustable mixing’’. Intuitively, this makes sense
because for cycling periods below the average length of stay (in our
standard setting 6.8 days), at a given time point the patients in the
ward will have started their therapy in different phases of the
cycling regime, and will therefore be treated with different drugs.
Thus, ‘‘adjustable cycling’’ leads to a similar heterogeneity in drug
use as ‘‘adjustable mixing’’. For very long periods, ‘‘adjustable
cycling’’ performs worse than ‘‘adjustable mixing’’. This is because
cycling with long periods is almost equivalent to strict mono-
therapy, leading to high frequencies of the currently favored
single-resistant strain (Figure 3D, S2, and S3). However, we find
for most parameter settings that ‘‘adjustable cycling’’ outperforms
‘‘adjustable mixing’’ for a range of intermediate periods (Figure
S4).
The success of ‘‘adjustable cycling’’ might be attributable to
extinction of strains that are resistant to the antibiotic that is
currently unused. Surprisingly, adjustable cycling performs worse
in stochastic models, falsifying that hypothesis (Figure 3, S2, and
S3). Our findings are in contrast to earlier studies that employed
deterministic models [5,6], which have argued that cycling always
performs worse than mixing. In particular, it was argued that the
disadvantage of cycling is monotonically increasing with the
cycling period [5].
We tested which of our model assumptions changes the
predictions so fundamentally. Unlike previous work, our model
distinguishes between asymptomatically colonized and symptom-
atically infected patients. In particular, we make the realistic
assumption that treatment is adapted if an asymptomatically
colonized patient progresses to symptomatic disease. For instance,
patients receiving prophylaxis with drug A are switched to drug B
upon progression. We compared our chosen endpoints as well as
the prevalence of different genotypes either with (Figure 3 A and
C) or without (Figure 3 B and D) this adjustment of treatment.
When assuming that there was no progression from colonization to
symptomatic infection, the number of colonized patients raised
monotonically with the period (Figure 3 B) as observed by
Bergstrom et al. [5]. Why does an adjustment of therapy make
‘‘adjustable cycling’’ effective? The most pronounced difference is
that the prevalence of singly resistant pathogens is lower with the
adjustments (Figure 3 C and D). This is because the treatment
Figure 1. Effect of clinical cycling vs. baseline period. A) This figure shows the effect of clinical cycling on total incidence rate, weighted
incidence rate of resistance, and mortality as estimated by a multivariate random-effects model. B) Performance of clinical cycling and pre-existing
resistance. On the x-axis, the average number of resistances per isolate during the baseline period against antibiotics used in the clinical cycling
regimen are given. On the y-axis, the success of clinical cycling as measured in the difference of total isolates per 1000 patient days is given. The error
bars indicate the standard deviation for each study. The p-value as well as the slope of the regression line (red line) with 95% confidence interval of
the regression is given in the figure. One study [49] was omitted because of insufficient data. C) Pathogen-specific meta-analysis. Our outcome
measures were the total number of isolates (black) and the weighted prevalence of resistance to the scheduled antibiotics (red). The number of
studies giving data on the respective pathogen group is given in brackets (black=total number, red=resistant). Due to the sparsity of the data for
individual pathogens, we used the Mantel-Haenszel method. Empty symbols indicate pathogen groups for which the omission of one single study
changed the relative benefit of clinical cycling (e.g. clinical cycling was beneficial when all studies were considered, but the omission of one of these
studies led to a detrimental outcome or vice versa).
doi:10.1371/journal.ppat.1004225.g001
Table 1. Outcomes adjusted for confounders.
Endpoint Adjusted for antibiotic usage and heterogeneity Adjusted for import into hospital
difference total incidence rate/1000 patient days 27.5 [212.3, 22.6] 29[ 218.5, 0.4]
difference resistance incidence rate/1000 patient days 210.0 [220.3, 0.2] 23.0 [215.3, 9.3]
difference deaths/1000 patient days 0.4 [22.6, 23.5] 22.6 [25.9, 20.7]
This table shows how the obtained results are affected by commonly criticized confounders. To adjust for differences in antibiotic usage and heterogeneity, we
predicted new estimates for univariate with the function predict() as implemented in the package metafor in R. Here, antibiotic heterogeneity is defined with the
antibiotic heterogeneity index, AHI~1{
n
2(n{1)
X
abs(1=n{ai) with n=number of employed antibiotics and a =usage of antibiotic a/total antibiotic usage. i
To adjust for antibiotic heterogeneity and consumption, we predicted the estimates for the hypothetical case that the ratio of daily defined doses and antibiotic
heterogeneity indices is 1, i.e. exactly equal antibiotic consumption and heterogeneity in both study arms. For predicting the difference when controlling for hospital
import, we predicted estimates for the hypothetical case that all studies only report isolates of strains that the respective patients were neither colonized nor infected
with at admission.
doi:10.1371/journal.ppat.1004225.t001
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current treatment during a particular cycling period. At the same
time, a substantial amount of resistant infections is washed out by
asymptomatic carriers leaving the hospital. Due to this fast decline
and the slow rise of resistance, a previously restricted drug can be
successfully re-employed in the next cycling period.
As mentioned above, one aim of this study was to investigate
whether we could find theoretical explanations for potentially
divergent recommendations depending on hospital settings or
differences in pathogen biology. To this end, we screened a very
large parameter space (see material and methods and text S1). We
defined the optimal period as the period most successfully reducing
inappropriate treatment without leading to an increased prevalence
of symptomatic infections (Figure S4). A sensitivity analysis
describing how the optimal period can be found in the supplemen-
tary material (Figure S5, S6, and S7). In our model, ‘‘adjustable
cycling’’ with a fixed period of 30 days was often successful and
rarely clearly disadvantageous. Despite enormous improvements in
some settings when individually adjusting the period for each
setting, the optimal period only performed 1.6% (median) better
than a fixed period of 30 days. A detailed analysis of the influence of
specific disease and hospital characteristics is given in the text S1. In
accordance with the results of our meta-regression, adjustable
cycling is especially advantageous if multiple resistance has not risen
to high frequencies yet but is likely to rise further.
Discussion
The question when to use cycling or mixing has been
controversially debated [10], and clinical and theoretical studies
came to different conclusions [5–7,9,10,61]. There are two
possible explanations for this divergence between theory and
clinical observations and potentially between different pathogens:
We might not have sufficient data on population-wide resistance
emergence. Alternatively, specific settings or differences in
pathogen biology might not have been adequately captured in
theoretical models so far.
We employed a method for a quantitative multivariate random-
effects meta-analysis using incidence rates as endpoints and find
that cycling reduced the incidence rate for both total infections
and resistant infections. Our findings remain robust in uni- and
multivariate metaregressions.
Figure 2. Dynamics during ‘‘adjustable mixing’’ and ‘‘adjustable cycling’’ periods of different length. The prevalence of
symptomatically infected patients by strain genotype during deterministic realizations of scenario ii) (single-resistance among incoming patients)
are shown. Red indicates resistance to drug A, blue indicates resistance to drug B, purple resistance to both drugs, and black the overall prevalence.
Graph A) shows the dynamics during mixing, B)–D) during cycling with increasing period length. The grey vertical lines indicate a period change.
doi:10.1371/journal.ppat.1004225.g002
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study outcome by meta-regressions. Regressions with a single
potential confounder are simplifications and might bias our results.
However, if the results of the meta-regressions and the mathe-
matical model are in concordance, it is justified to suggest that the
tested factors influence the success of cycling. Indeed, we found
that clinical cycling reduced the number of total infections when
the pathogens isolated during the baseline period had a low
average number of resistance genes to the drugs employed in the
cycling regimen. This is in line with our and previous theoretical
results arguing that cycling is effective in preventing the evolution
of multiple resistance, but that there is little difference once
multiple resistance is wide-spread [5,6,62].
In our analysis, we assume that the baseline period most closely
resembles ‘‘adjustable mixing’’. However, physicians might tend to
prescribe drugs that both cover a broad spectrum of pathogens
and which they are familiar with. Additionally, they may be asked
to use the substance that has the lowest cost. These restrictions
may lead to a predominance of one drug. Furthermore, there is
only one clinical study simultaneously comparing mixing and
cycling [63]. Finally, the implementation of a study might alter
prescribing behavior [60]. We examined these confounders by
adjusting for different AHIs (antibiotic heterogeneity indices) [28],
as well as the total volume of antibiotic consumption (measured in
daily defined doses, DDD). These adjustments did not generally
change the outcome.
Another potential confounder may be differences in the influx of
resistant pathogens into the hospital. Some of the studies we
analyzed controlled for this confounder. Additional adjustment for
the differences in these two study groups further widened the
confidence interval such that all differences became statistically
insignificant, while the general trend towards a positive effect of
clinical cycling remains. Although adjustment leads to less clear
results, we would expect that confounders are comparable for all
considered pathogens and confounders therefore do not explain
the divergent findings for different pathogens. Moreover, the
adjusted endpoints are not uniformly shifted towards a less
favorable outcome. This indicates that the observed success of
clinical cycling is not solely attributable to confounders that were
most criticized [11]. Despite testing for publication bias (data not
shown), we cannot exclude that unsuccessful studies were not
published. However, we chose a new composite outcome
(weighted incidence rate of resistance), making publication bias
for this particular measure less likely.
Nosocomial infections can be caused by a large variety of
bacterial pathogens. We therefore repeated our analysis for
important pathogen groups and bacterial species. Again, the
overall effect of clinical cycling was beneficial, especially in
reducing resistance. Surprisingly, we observed large differences
between different pathogens. The detrimental effect of clinical
cycling regarding infections caused by enterococci might be
partially explained by the fact that one study used linezolid and
Figure 3. Cycling is successful when treatment is adjusted. The schematic on the left illustrates treatment adjustment upon progression. A
patient colonized (C) with an A-resistant pathogen as indicated by red circles and receiving drug A progresses to symptomatic disease (I) because the
current drug is ineffective. Upon progression, the therapy under which the patient deteriorated is switched to drug B. This drug is effectively clearing
the infection and the patient becomes susceptible (S) for new colonization. The left panel (A, C) shows a scenario where treatment is adjusted upon
progression, the right panel (B, D) shows the same parameter without treatment adjustment. We modeled the scenario without treatment
adjustment by setting the progression rate to zero, the treatment frequencies for colonized patients were adjusted to correspond to the overall
treatment frequencies in our standard settings. The x-axis gives the period length, the y-axis the prevalence of single-resistant carriers relativet o
Mixing. The upper panel (A, B) shows the prevalence of colonized (green), symptomatically infected (black) and symptomatic patients who are
inappropriately treated (grey). The lower panel (C, D) shows the genotype composition depending on the period length: red indicates resistance to A,
blue resistance to B, and purple resistance to both drugs. The dotted black line indicates no difference in prevalence.
doi:10.1371/journal.ppat.1004225.g003
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cin-resistant enterococci (VRE) in the vancomycin periods [54].
Also from previous theoretical studies as well as our theoretical
results, we expect that cycling favors singly-resistant pathogens.
The study design of many clinical studies had been criticized
before [11]. Based on the available studies that fulfill our selection
criteria, our meta-analyses consistently show that clinical cycling is
beneficial. To strengthen this finding, we used mathematical
modeling to investigate the underlying mechanisms that explain
our results. This theoretical epidemiological model specifically
addresses the situation in hospitals and can be adapted to a
multitude of infectious diseases. Importantly, our model allows
adjusting ineffective treatment. These ‘‘adjustable strategies’’ are
different from the strict cycling and mixing modeled in previous
theoretical work, but is likely to be closer to clinical reality.
The flexibility of our model enables us to identify the optimal
period for a large parameter-range for several settings. This is
essential for elucidating the influence of pathogen biology on
optimal treatment strategies. Our model includes many of the
characteristics of hospital wards that were not considered in
previous models. However, we made simplifications that are
discussed below. These simplifications were necessary because
screening a large parameter space would become impossible with
increasing model complexity. Importantly, for parameter settings
corresponding to those in earlier models we come to the same
conclusions.
We assume that resistance always fully protects from the effects
of the antibiotics and neglect any within-host dynamics. We only
model a single hospital ward and assume that the composition of
incoming patients is constant. In our modeling framework, the
susceptible state is a result of previous antibiotic therapy. It
indicates that a patient’s microflora has been disturbed to a degree
that other strains can easily invade. Despite the large numbers of
bacteria in the microflora in colonized patients, their numbers
likely decline when treated with an antibiotic for which they are
susceptible. This process would be most accurately described by a
continuous decline of infectiousness, which may never reach zero.
However, to keep our model tractable, we assume that the
bacterial load in the microflora is reduced to an extent that
transmission of a strain susceptible to the used antibiotics is
negligible compared to the infectious pressure by fully colonized or
infected patients.
Furthermore, we assume that the mutation rates to resistance
are constant. With plasmid-borne resistance, the rate of resistance
acquisition depends on the abundance of both donor- and
acceptor strains. Thus, our model reflects chromosomal resistance
more accurately than plasmid-borne resistance. However, muta-
tion rates have a negligible influence once resistance is brought in
by incoming patients. We therefore do not expect that the results
of our model would change substantially when taking different
modes of resistance acquisition into account.
Naturally, there is an enormous biological diversity in all
pathogens that cause nosocomial infections. Thus, we would
expect differences in the speed of resistance emergence and
spread. Here, we focus on the question, which salient properties of
these bacteria determine which treatment strategy will be most
successful. One important factor we identify in all our analyses is
the rate of emergence of multiple resistance. In our general meta-
analysis we found that the baseline prevalence of resistance
strongly affects the success of cycling. Consistent with these results,
we observe in our model that ‘‘adjustable cycling’’ can suppress the
emergence of multiple resistance. This is the case when multiple
resistance is not present in incoming patients, but would emerge de
novo in the ward during ‘‘adjustable mixing’’, i.e. with high
mutation rates in the stochastic model and more generally in the
deterministic model. The fact that ‘‘adjustable cycling’’ is even
more effective in a deterministic model indicates that extinction
events during the off-periods play only a minor role and cannot
explain potential advantages of cycling. This is in contrast to
making use of extinction in informed switching, where treatment is
switched depending on current resistance frequencies [64].
Unsurprisingly, these results only hold when the single-resistant
strains have a competitive advantage over the double-resistant
strain in each cycling period.
The optimal period depends on the emergence of double-
resistant strains and the generation time (time between the
infection of a patient and the transmission to the next patient).
These factors are not always known, but a period length of 30 days
performed well in nearly all settings. When in doubt, a shorter
period seems to be more beneficial, because there is no difference
between ‘‘adjustable cycling’’ and ‘‘adjustable mixing’’ when the
period length is shorter than the generation time, while too long
periods are equal to treating with only one drug. Despite the lack
of correlation between number of used drugs and study outcome
in the meta-analysis, it would also be interesting to develop
theoretical models with more than two drugs. From previous
theoretical studies [6], we would expect that cycling improves as
more drugs are included, because resistance against a specific drug
would decline to lower levels until this drug is reintroduced.
Most importantly, the findings of our meta-analysis agree well
with our theoretical results. Both the meta-analysis as well as the
theoretical model shows that cycling is beneficial if there is
emerging or a low influx of double-resistance. Thus, our model
incorporates an important, previously disregarded factor that
changes treatment recommendations. Clearly, more pathogen-
specific studies of larger scales are needed to answer in which
pathogens cycling is beneficial.
Methods
Meta-analysis
Study selection. A literature search was performed on
PubMed in the Medline database using ‘hospital’’ combined with
two of the following terms: i) ‘antibiotic’, ‘antimicrobial’ or
‘antibacterial’ and ii) ‘cycling’, ‘rotation’ or ‘scheduled changes’.
For a search on Google Scholar we required i) and ii) to be linked,
i.e. either ‘‘i) ii)’’ or ‘‘ii) of i)’’ to minimize false-positive hits in the
full text search. Reference lists of all retrieved original papers and
of review articles were hand-searched to identify further relevant
studies. We identified 46 clinical studies addressing the effect of
cycling on nosocomial infections (Figure S1).
Inclusion/exclusion criteria. We defined cycling as repeat-
ed rotations of at least two antibiotics in the same order. This
criterion was met by 25 studies (Figure S1) Furthermore, we
required a baseline period in the same ward or comparison to
simultaneously recorded data from a ward in the same hospital
and that no other infection control measures were introduced in
the observation period. In total, 11 studies were eligible, i.e.
fulfilled our criteria and provided all needed data (Figure S1).
Endpoints. We chose the number of total isolates and
resistant isolates per patient day as primary endpoints and
deaths/patient day as secondary endpoint. To be able to compare
the results to our model, we only included resistance against the
scheduled antibiotics and summed over all resistances, such that
we count resistance genes rather than the number of isolates
resistant against at least one drug. This measure is related to the
number of inappropriately treated patients, since appropriate
treatment becomes less likely with increasing resistance levels.
Cycling Empirical Antibiotic Therapy
PLOS Pathogens | www.plospathogens.org 7 June 2014 | Volume 10 | Issue 6 | e1004225Since not all studies gave the number of patient days, we used the
number of beds in ward or in the hospital multiplied with observed
period as a proxy when necessary.
Data extraction. Data were extracted independently by two
investigators (PAzW and SA). Differences were resolved by
discussion with a third investigator (RK). The extracted data are
given in table S2. For one study [45], both a temporal and a spatial
control were given. Three studies reported both total and only
acquired pathogens [11,50,54]). To minimize heterogeneity, we
chose the temporal control and total isolates. However, when
adjusting for possible confounding (Table 1), we used the
difference in the three studies reporting both total and acquired
pathogens. Regarding antibiotic usage, the level of detail in
reporting was very variable. To calculate antibiotic heterogeneity
([28], Table 1), we used all data reported in each study regardless
of how comprehensive they are.
Data analysis and statistical methods. We used the
metafor package [65] in the statistical software package R (version
3.0.2). For analyzing the incidence rates of all reported pathogens,
the pooled rate differences and 95% confidence intervals (CIs)
were calculated using data provided in each study. For the data on
infections caused by all bacterial species, these were obtained using
a random-effects multivariate meta-analysis of the three endpoints
simultaneously ([66–68] see supplementary material).
Since the data for single pathogens are sparse, we used the
Mantel-Haenszel method and evaluated the stability of the results
with leave-one-out sensitivity analyses. Between-study heteroge-
neity was examined using the Q statistic and the I2 statistic [69].
Publication bias was assessed using plots of study results against
precision of the study (funnel plots). Symmetry of the funnel plots
was tested using the methods suggested by Egger et al. [70] and
Begg and Mazumdar [71]. Given the detected high degree of
heterogeneity of the incidence rate differences, we subsequently
conducted meta-regression analyses to explore pre-defined sources
of heterogeneity.
Epidemiological model
We assess the outcome for a timeframe of ten years to account
for the fact that the expected time for the availability of new
broad-spectrum antibiotics is in the range of a decade. We
performed all analyses with a stochastic and a deterministic
version, which describe small populations (i.e. single wards) and
large populations (i.e. entire hospitals), respectively. In preliminary
analyses, we found that transmission mode and the proportion of
incoming resistant strains were the factors that lead to the greatest
changes in model predictions. Therefore, we chose a total of six
standard scenarios. We consider two transmission modes: delayed
transmission via contaminated surfaces and direct transmission.
Both transmission modes were analyzed for three settings: either i)
no pre-existing resistance in the community, ii) pre-existing single-
resistance or iii) both single and double-resistance pre-exist. For
these six standard scenarios, each of the 22 model parameters was
varied over a clinically relevant range (Table S6), while all other
parameters were kept at default values. All periods were chosen
such that we evaluate the success at 3600 days exactly at the end of
a period where the second antibiotic (B) was employed. For all six
settings, we screened the combination of all default values by
varying the period length over all integer divisors of 1800 (i.e.
1800, 900, 600, …, 2, 1). When varying single parameters in each
of the six standard settings, we chose a subset between 5 and 360
days (Figure S4).
The model we use in this study is based on a model we used
previously [64,72]. We consider a compartmental epidemiological
model that aims at describing a single hospital ward (for an
overview over the parameterization see Table S6). We assume that
two broad-spectrum antibiotics are available for empirical
treatment. We will refer to these as drug A and B. Accordingly,
we follow four genotypes (Figure S8): wild type (sensitive to both
drugs), resistant to A, resistant to B, and resistant to both drugs.
Resistance can be acquired via mutations, which occur at rates ma,
mb and mab, the subscript denotes the drug against which resistance
is acquired. The parameter masym describes mb relative to ma, while
keeping the resulting mab constant. For simplicity, we make the
assumption that there is no cross-resistance, meaning there is no
additional selection pressure for A-resistance or B-resistance other
than by drug A and B, respectively.
Patients are classified as being protected (P, e.g. intact
microflora), susceptible (S), colonized (C; i.e. asymptomatic
carriers), or infected (I; i.e. symptomatic carriers) (Figure 4). In
this context the susceptible state is a result of previous antibiotic
therapy. It indicates that a patient’s microflora has been disturbed
to a degree that other strains can easily invade. Furthermore, we
assume that the bacterial load in the microflora is reduced such
that transmission of a strain susceptible to the used antibiotics
ceases.
We assume that both mortality and morbidity only differ in
symptomatically infected patients, the additional mortality in these
patients is given by the parameter d, the reduced likelihood of
leaving the hospital when infected by the parameter rI. With long-
term treatment, protected patients may proceed to the susceptible
compartment after a time tcl,P. We consider two transmission
modes; either immediate transmission (also appropriate for
transmission without a time-lag via health care workers) or
delayed transmission. The latter occurs via a pathogen reservoir
outside the patients (E), which describes most appropriately
environmental contamination. It may also describe the dynamics
resulting from the transient colonization of health care workers,
although these are not modeled explicitly. Patients are first
asymptomatically colonized and may then progress after a time tp.
The time to clearance tcl when treated appropriately is the same
for both colonized and infected patients. The compartments C and
I are divided in subcompartments according to the carried
genotype (wt, A-, B- or AB-res).
We assume a fixed number of beds (20) in the hospital ward. As
soon as a bed is free, new patients are admitted within a day,
resulting in an average population size of ,17 patients per ward
(85% occupancy). The composition of the incoming patients
regarding colonization and resistance status is assumed to be
constant over the observed timeframe. These frequencies are
described using the parameters in table S6, section 2. The
proportion of patients carrying resistant and double-resistant
strains is given by pres and pab, respectively, the relative proportions
of A- and B- resistance are given by pasym (if this is 0.5, both strains
are found at equal frequencies). To follow treated patients, all
compartments are subdivided according to the treatment status
(Figure 5). Since we only investigate resistance to drug A and B, we
do not take any other drugs into account. Infected patients are
treated per default according to the current treatment strategy
(‘‘adjustable mixing’’ or ‘‘adjustable cycling’’) as soon as they enter
the hospital or progress to the infected compartment.
Here, we consider ‘‘adjustable strategies’’, i.e. we assume that in
patients that progress while they are treated, the treatment is
switched. Furthermore, we assume that susceptible patients cannot
be infected with a strain when treated with a drug the pathogen is
susceptible for. A certain fraction of patients that are not
symptomatically infected with the considered pathogen may also
receive treatment with the scheduled drugs. The frequency of such
treatment, which we call here prophylaxis, is given by fp, and
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currently scheduled therapy. In addition, some patients may
receive both drugs, this is denoted by fp,AB. Figure S9 gives the
average treatment frequency during one strategy. Around seven of
seventeen patients (41%) receive either of the scheduled drugs at
any point in time. Once an infected patient is assigned to a drug,
Figure 4. Compartmental model for single strain. Explanations of the parameters, their standard values, the range over which we varied these
parameters, as well as references are given in table S6. The compartments are: P=protected patients; S=susceptible patients; C=colonized patients;
I=infected patients; E=environment. The color coded arrows indicate: violet=environmental contamination & decay; blue=admission & mortality/
discharge; green=decolonization & recovery (this does not necessarily indicate full clearance of the pathogen from all body compartments, rather, it
describes that the bacterial population has decreased sufficiently to allow a new strain to take over); orange=progression; red=transmission.
doi:10.1371/journal.ppat.1004225.g004
Figure 5. Treatment algorithm. The superscript denotes the treatment status. Colonized patients are assigned with frequencies fp and fp,AB to
treatment for other causes than symptomatic infections with the organism under consideration. If they progress to symptomatic disease and were
previously treated with a single drug, this drug is then switched, while patients on both drugs remain on their treatment. Infected patients are
assigned to treatments according to the current treatment strategy (mixing or cycling) immediately upon entering the ward.
doi:10.1371/journal.ppat.1004225.g005
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treatment is inappropriate (for example treatment with drug A for
an A-resistant infection), in which case it is switched with a rate s.
The biology of different infectious diseases is described with the
parameters of table S6, section 3. These determine a) how fast de
novo resistance may arise in individual patients, b) the costs of
these resistance mutations, which are assumed to lower transmis-
sion probability, c) the rates with which patients can recover after
treatment, d) the increase in mortality by the disease and finally e)
how fast colonized patients become symptomatic.
We consider both a deterministic and a stochastic version of the
model described above. The deterministic model is implemented
by numerically solving the ordinary differential equations (ODEs)
that correspond to figures 4, 5 and S8. The stochastic model is
derived from these ODEs by considering transition between
compartments as stochastic events according to the Gillespie
algorithm. All codes are available upon request.
Supporting Information
Figure S1 PRISMA flowchart.
(PDF)
Figure S2 Influence of period length on ‘‘adjustable
cycling’’ success and genotype composition. Results of
stochastic simulations with parameters for scenario ii (single-
resistance present among incoming patients) and direct transmis-
sion. A) Relative change of inappropriately treated patients (open
grey diamonds) and symptomatically infected patients (solid black
circles) as compared to ‘‘adjustable mixing’’. B) same as A with
higher resolution. C) Relative change of genotype composition
depending on the period length as compared to ‘‘adjustable
mixing’’: black indicates wild-type, red resistance to A, blue
resistance to B, and dotted purple resistance to both drugs. D)
same as C) with higher resolution. The 95% CI, as determined by
bootstrapping, is given as error bars. Please note that the error
bars for all measures except the prevalence of double-resistance
are smaller than the used symbols.
(PDF)
Figure S3 Influence of period length on cycling success
and genotype composition, environmental transmis-
sion. For all simulations, parameters for scenario ii (single-
resistance present among incoming patients) and environmental
transmission were used. A) Relative change of inappropriately
treated patients (open diamonds) and symptomatically infected
patients (solid circles) as compared to mixing for a deterministic
realization. B) Same as A) for a stochastic realization. C) Relative
change of genotype composition depending on the period length
as compared to mixing: black indicates wild-type, red resistance to
A, blue resistance to B, and dotted purple resistance to both drugs.
The 95% CI, as determined by bootstrapping, is given as error
bars. D) Same as C) for a stochastic realization.
(PDF)
Figure S4 Overview over optimal cycling periods and
success of these periods. A) For stochastic simulations if no
resistance pre-exists in the incoming patients (scenario i). The
results were obtained by averaging over 10000 simulations.
Parameters (explained in table S6) were varied from a) (lowest)
to g) (highest, see table S6) and the effect on the relative reduction
of inappropriately treated patients as compared to mixing is
indicated by green color code for an optimal period length. The
optimal period was defined as the period that is most successful in
reducing inappropriate therapy without leading to a higher
prevalence of symptomatic infections and its length is indicated
by red color code. The areas shaded in grey indicate that there is
no period (within our screened range) for which cycling
outperforms mixing. B) For stochastic simulations if only single-
resistance pre-exists in the incoming patients (scenario ii). The
results were obtained by averaging over 10000 simulations.
Parameters (explained in table S6 were varied from a) (lowest) to
g) (highest, see table S6 and the effect on the relative reduction of
inappropriately treated patients as compared to mixing is
indicated by green color code for an optimal period length. The
optimal period was defined as the period that is most successful in
reducing inappropriate therapy without leading to a higher
prevalence of symptomatic infections and its length is indicated
by red color code. The areas shaded in grey indicate that there is
no period (within our screened range) for which cycling
outperforms mixing. C) For stochastic simulations if both single
and double-resistance pre-exist in the incoming patients (scenario
iii). The results were obtained by averaging over 10000
simulations. Parameters (explained in table S6) were varied from
a) (lowest) to g) (highest, see table S6 and the effect on the relative
reduction of inappropriately treated patients as compared to
mixing is indicated by green color code for an optimal period
length. The optimal period was defined as the period that is most
successful in reducing inappropriate therapy without leading to a
higher prevalence of symptomatic infections and its length is
indicated by red color code. The areas shaded in grey indicate that
there is no period (within our screened range) for which cycling
outperforms mixing. D) For deterministic simulations if no
resistance pre-exist in the incoming patients (scenario i). Same as
Figure S4A for deterministic simulations. E) For deterministic
simulations if single-resistance pre-exists in the incoming patients
(scenario ii). Same as Figure S4B for deterministic simulations. F)
For deterministic simulations if both single and double-resistance
pre-exist in the incoming patients (scenario iii). Same as Figure
S4C for deterministic simulations.
(PDF)
Figure S5 Influence of admission of susceptible patients
and time between first and second transmission. The
lines represent the averages of 10000 stochastic simulations; the
error bars the 95% CI as determined by bootstrapping. The red
line indicates the standard parameter setting. A) Shows an
example of increasing the influx of susceptible patients (from
0%, given in black in 15% steps to 90%, given in light grey).
Simulations for direct transmission for scenario ii (only single-
resistance among incoming patients) are shown. B) Shows an
example of increasing the time between the colonization of a
patient and the transmission of the pathogen by increasing the
environmental decay rate (from 1 day, given in black over 2, 5, 7,
10, 20 to 100 days, given in light grey). Simulations for
environmental transmission for scenario ii (only single-resistance
among incoming patients) are shown. The dotted black line
indicates no difference in prevalence.
(PDF)
Figure S6 ‘‘Adjustable cycling’’ success depends on
fitness of double-resistant strain. These graphs show how
the suppression of double-resistance depends on the fitness of the
double-resistant strain (color code on the right). The parameter
setting corresponds to scenario ii (single-resistance among
incoming patients) for direct transmission. The upper panel (A,
B) gives the prevalence of inappropriately treated patients relative
to mixing; A) for deterministic realizations and B) for the stochastic
realizations. The 95% CI, as determined by bootstrapping, is
given as error bars, however, these are smaller than the line width.
The lower panel (C, D) gives the prevalence of double-resistant
Cycling Empirical Antibiotic Therapy
PLOS Pathogens | www.plospathogens.org 10 June 2014 | Volume 10 | Issue 6 | e1004225strains relative to mixing; C) for deterministic realizations and D)
for the stochastic realizations. The 95% CI, as determined by
bootstrapping, is given as error bars.
(PDF)
Figure S7 Selection pressure depending on period
length and main factors influencing the optimal period.
A) Classification of period lengths in three groups, on the example
of a stochastic realization of the standard setting for scenario ii
(single-resistance present among incoming patients). i) red
indicates those periods for which there is no difference between
‘‘adjustable mixing’’ and ‘‘adjustable cycling’’, ii) green indicates
those periods, which select against single-resistance and for
double-resistance, iii) black those that both increasingly select
against double-resistance and increasingly allow outgrowth of
single-resistant strains. B) to D) show examples of the main factors
influencing the location and success of the optimal period, the
arrows summarize the trends which occur by changing these
factors. B) Influence of the difference between the prevalences of
the single resistant strains during the on- and off-periods in
‘‘adjustable cycling’’. The black line indicates the standard value as
in A), the grey line indicates a setting with more incoming
susceptible patients C) Influence of the turnover rate on the
optimal period. The black line indicates environmental transmis-
sion with a decay rate of one day (note the similarity to the
standard setting for direct transmission), the grey line indicates
environmental transmission with a decay rate of 30 days. D)
Influence of suppression of double-resistance on optimal period.
Here, we chose a deterministic realization, because the variability
of the emergence of double-resistance is large in stochastic
simulations. The black line indicates the standard setting for
scenario ii (single-resistance present among incoming patients), the
grey line indicates a setting where the costs of double-resistance are
50% and it is therefore not competitive.
(PDF)
Figure S8 Considered genotypes and frequency with
which infected patients become non-susceptible. The
grey, red and blue boxed indicate resistance gene loci on the
bacterial chromosome (black circle). Grey boxes with a ‘+’
represent wild-type alleles, red boxes with ‘a’ and blue boxes with
‘b’ represent alleles that confer resistance to drug ‘A’ or ‘B’,
respectively. Transitions between genotypes are represented by
arrows and the respective mutation rate for each transition is
indicated by ‘mx’.
(PDF)
Figure S9 Treatment frequencies for standard param-
eter setting for stochastic realizations of scenario ii
(single-resistance, but not double-resistance pre-exists).
Red lines indicate patients being treated with drug A, blue lines B-
treated patients. Only the last 1.5 years are shown to illustrate
long-term dynamics. For each strategy, the average of 500 runs is
shown.
(PDF)
Table S1 PRISMA checklist.
(PDF)
Table S2 Overview of study characteristics and extract-
ed data. A) Study characteristics. Abbreviations: pip/taz=piper-
acillin/tazobactam, imi/cil=imimpinem/cilastin, tic/clav=ticar-
cillin/clavulanic acid. B) Extracted data. * AHI~1{
n
2(n{1)
X
abs(1=n{ai) with n=number of employed antibiot-
ics and ai=usage of antibiotic a/total antibiotic usage.
(PDF)
Table S3 Results of univariate meta-analysis.
(PDF)
Table S4 Results of meta-analyses under inclusion of
acquired instead of the total isolates in [50,52]. All other
used data are the same as in figure 1 in the main text.
(PDF)
Table S5 Results of meta-analyses under inclusion of
the contemporary instead of the historic control arm in
[45]. All other used data are the same as in figure 1 in the main
text.
(PDF)
Table S6 Overview over parameters. A) Ward character-
istics [73]. * The average length of stay is 8 days in Switzerland
(http://www.obsandaten.ch/indikatoren/5_4_1/2005/d/541.pdf,
data from 2005) and 5 days in the US (http://www.cdc.gov/
mmwr/preview/mmwrhtml/mm5427a6.htm). ** Pennsylvania
Health Care Cost Containment Council. Hospital-acquired
Infections in Pennsylvania 2005, 2006 & 2007. Available:
http://www.phc4.org/reports/hai/(2011). ***x was chosen arbi-
trarily. However, bE is adjusted such that R0 remains constant for
both direct and environmental transmission or any mixture of
these two transmission modes. B) Composition of incoming
patients [74]. C) Disease biology [1] [75–77] [78,79] [80,81]. *
‘‘Colonization pressure’’, i.e. the frequency of both asymptomatic
and symptomatic carriers in a hospital ward has been shown to be
a major risk factor for the acquisition of a nosocomial pathogen
[82]. It also has been shown for Clostridium difficile, that
environmental contamination occurred for both symptomatic
and asymptomatic infections [83]. Nevertheless, it is conceivable
that e.g. in symptomatically infected patients with diarrhea
infectivity is much higher than in asymptomatic patients.
However, since the connection between carriage and infection is
established and data on potential differences in infectivity between
symptomatic and asymptomatic patients are scarce, we chose not
to distinguish between these two classes. D) Treatment character-
istics.
(PDF)
Text S1 Detailed description of meta-analysis (method,
extracted data and sensitivity analysis) and sensitivity
analysis of theoretical model.
(DOCX)
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